How does aplastic anemia develop and what are its clinical manifestations?

How Aplastic Anemia Develops and Its Clinical Manifestations

Aplastic anemia is a bone marrow failure syndrome characterized by pancytopenia and bone marrow hypocellularity, resulting from destruction of hematopoietic stem cells through immune-mediated mechanisms, direct cellular injury, or intrinsic stem cell defects.

Pathophysiology: Three Primary Mechanisms

The development of aplastic anemia involves three interconnected pathogenic mechanisms 1, 2:

1. Immune-Mediated Destruction (Most Common)

• Cytotoxic T cell attack: Activated cytotoxic T lymphocytes specifically target and destroy autologous hematopoietic stem and progenitor cells 1, 2
• Inflammatory cytokine damage: Elevated levels of interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) in bone marrow and peripheral blood directly suppress hematopoiesis 1
• Altered T cell ratios: Changes in T lymphocyte populations drive disease progression 2
• This mechanism explains why immunosuppressive therapy is effective in more than half of cases 1

2. Direct Stem Cell Injury

• Physical factors: radiation exposure
• Chemical agents: toxins, certain medications
• Biological agents: viral infections (particularly hepatitis viruses, EBV, CMV, parvovirus) 3, 1
• These insults cause quantitative reduction in pluripotent hematopoietic stem cells 1

3. Intrinsic Stem Cell Abnormalities

• Clonal hematopoiesis: Some patients develop blood cells derived from a single abnormal stem cell clone 1
• Genetic susceptibility: Single-nucleotide polymorphisms (SNPs) in key genes influence disease susceptibility, severity, and treatment response 4
• This mechanism explains the increased risk of evolution to paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), or acute myeloid leukemia in long-term survivors 1

4. Bone Marrow Microenvironment Dysfunction

• Both hematopoietic stem cells and mesenchymal stromal cells are impaired 2
• The protective substrate for hematopoietic cells becomes damaged 2
• However, studies show the microenvironment is normal in the vast majority of cases 1

Clinical Manifestations

Hematologic Presentation

Pancytopenia is the defining feature 5, 6:

• Anemia: Fatigue, weakness, pallor, dyspnea
• Thrombocytopenia: Petechiae, bruising, mucosal bleeding (but NOT hepatosplenomegaly or hemolysis—these suggest alternative diagnoses) 7
• Neutropenia: Recurrent infections, fever

Severity Grading 3

The severity directly impacts prognosis and treatment selection:

• Severe AA: ANC <500/μL, platelet count <20,000/μL, reticulocyte count <20,000/μL, plus hypocellular marrow <25%
• Very Severe AA: ANC <200/μL with other criteria met
• Moderate AA: Hypocellular marrow <25% and two of the following: ANC <500/μL, platelets <20,000/μL, reticulocytes <20,000/μL
• Mild AA: ANC >500/μL, hypocellular marrow <25%, platelets >20,000/μL, reticulocytes >20,000/μL

Bone Marrow Characteristics 6, 8

• Marked hypocellularity (<25% cellularity) is essential for diagnosis
• Absence of dysplastic features: Unlike MDS, morphology is normal (no ring sideroblasts, vacuoles, or dyserythropoietic changes) 7
• Progressive hypocellularity: The marrow becomes increasingly hypocellular over time, with 75% of steroid-refractory patients developing moderate to severe hypoplasia 7
• Secondary cytopenias may develop: 43% develop neutropenia and 29% develop thrombocytopenia over time 7

Age and Temporal Patterns

• Can manifest from in utero (hydrops fetalis) to the sixth decade of life 7
• 77% present with anemia in infancy, but delayed presentations are increasingly recognized 7
• Median age varies but affects elderly more commonly 9

Associated Complications

• Infection risk: Due to neutropenia, requiring antimicrobial prophylaxis in high-risk patients 10
• Bleeding risk: Correlates with platelet nadir; prophylactic transfusions recommended at <10,000-20,000/μL 11
• Evolution risk: Increased risk of PNH (detectable GPI-anchor protein deficiency in some patients), MDS, or AML in long-term survivors 1, 12
• Mortality without treatment: Approaches 70% within 2 years for severe AA 12

Critical Diagnostic Distinctions

Common pitfalls to avoid 6, 8:

1. Hypoplastic MDS: Distinguished by presence of dysplastic morphology and chromosomal abnormalities (particularly del(5q) or -7) 5, 6
2. PNH: Flow cytometry for GPI-anchored proteins (CD16, CD55, CD59) is essential 3
3. Inherited bone marrow failure syndromes: Require genetic testing and family history assessment 5, 7

Key diagnostic workup 3, 10:

• CBC with differential, reticulocyte count, peripheral smear
• Bone marrow biopsy and aspirate (biopsy is critical—aspirates are often paucicellular)
• Flow cytometry for PNH markers
• Viral studies (CMV, EBV, HHV6, parvovirus)
• Cytogenetic analysis (to exclude MDS)
• HLA typing (for transplant evaluation)
• Nutritional assessments (B12, folate, copper)

The diagnosis requires exclusion of all other causes of pancytopenia before confirming aplastic anemia 1, 8.